Boston Scientific Reports Q3 2026 Financial Results and Updates Full-Year Guidance

Boston Scientific reported third-quarter 2026 sales of $5.138 billion, up 1.5% year over year, and adjusted EPS of $0.73. It lowered full-year adjusted EPS guidance to $3.16–$3.18, citing pricing pressure in China and weakness in its electrophysiology and Watchman product lines. The company said its $14.5 billion acquisition of Penumbra is now expected to close in the first quarter of 2027 because of regulatory delays, with higher interest rates adding to the expected earnings drag. An August 2026 cybersecurity incident also hurt results, though operations have since been restored.